Insulet Corporation has announced the nationwide availability of the Omnipod® 5 App for iPhone, now integrated with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. This marks a significant step forward in diabetes technology by uniting tubeless automated insulin delivery with real-time glucose monitoring—all seamlessly managed through an iPhone. By eliminating the need for a separate controller, this integration simplifies daily diabetes management and empowers users with more choice, convenience, and control.

The Omnipod 5 system adjusts insulin delivery every five minutes, responds proactively to high glucose levels, and helps guard against hypoglycemia, providing round-the-clock support—even while users sleep. With the app now available for iPhone, users can bolus, change Pods, review trends, and adjust settings directly from their mobile device. This not only streamlines device management but also reduces the physical burden of carrying multiple devices, making diabetes care more intuitive and less intrusive.

This integration reflects Insulet’s ongoing commitment to delivering innovative, patient-centric solutions for people living with diabetes. As more users seek seamless, mobile-friendly options for managing their condition, the launch positions Insulet at the forefront of next-generation diabetes care. By combining two leading technologies—Omnipod 5 and Dexcom G7—into a unified, app-based experience, the company is redefining ease of use and accessibility, helping users achieve better outcomes with greater confidence.